Bohemine|cas:189232-42-6|西域试剂

Bohemine,98.93%

产品编号：Bellancom-12843| CAS NO：189232-42-6| 分子式：C₁₈H₂₄N₆O| 分子量：340.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-12843	￥600.00	杭州北京（现货）
Bellancom-12843	￥900.00	杭州北京（现货）
Bellancom-12843	￥2900.00	杭州北京（现货）
Bellancom-12843	￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Bohemine

产品介绍

Bohemine 是一种嘌呤类似物，也是一种合成的选择性的 CDK 抑制剂，对 Cdk2/cyclin E，Cdk2/cyclin A 和 Cdk9/cyclin T1 的 IC₅₀ 分别为 4.6 μM，83 μM 和 2.7 μM。Bohemine 还抑制 ERK2，IC₅₀ 为 52 μM，对 CDK1，CDK4 和 CDK6 的抑制作用较小。Bohemine 具有广泛的抗癌活性。

生物活性

Bohemine is a purine analogue and is a synthetic and selective CDK inhibitor with IC₅₀s of 4.6 μM, 83 μM, and 2.7 μM for Cdk2/cyclin E, Cdk2/cyclin A, and Cdk9/cyclin T1, respectively. Bohemine also inhibits ERK2 with an IC₅₀ of 52 μM and has less inhibitory effect on CDK1, CDK4 and CDK6. Bohemine has a broad spectrum anti-cancer activities.

体外研究

Bohemine (0-30 µM; 72 hours; ME-750 cells) treatment inhibits cell growth. Addition of Bohemine at concentrations in the range of 1-10 µM results in a short-term arrest of growth and of monoclonal antibody production. The short-term suppression of cell functions is followed by a significant temporary increase of specific growth rate and of specific production rate.
Hybridoma cells are retarded both at the G1/S boundary and at the G2/M boundary, depending on Bohemine (0-30 µM) concentration.
T-lymphoblastic cell line CEM is treated by Bohemine, five proteins are found to be downregulated, namely α-enolase, triosephosphate isomerase, initiation factor 5A, and α- and β-subunits of Rho GDP-dissociation inhibitor 1. These proteins play significant roles in glycolysis, proteosynthesis, and in cytoskeleton rearrangement.
Bohemine inhibits growth of human tumor cell lines with an IC₅₀ of 27 µM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Mouse hybridoma ME-750 cells
Concentration:	0 µM, 1 µM, 3 µM, 10 µM and 30 µM
Incubation Time:	72 hours
Result:	At 10 µM and 30 µM concentrations, the viable cell count was significantly lower with respect to control, i.e., 77% and 48%, respectively.

体内研究
(In Vivo)

Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice bearing the colon 26 murine tumor
Dosage:	50 mg/kg
Administration:	Intravenous injection (Pharmacokinetic Analysis)
Result:	C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

体内研究

Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice bearing the colon 26 murine tumor
Dosage:	50 mg/kg
Administration:	Intravenous injection (Pharmacokinetic Analysis)
Result:	C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

体内研究

Bohemine (50 mg/kg; intravenous injection; BALB/c mice) treatment shows C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c mice bearing the colon 26 murine tumor
Dosage:	50 mg/kg
Administration:	Intravenous injection (Pharmacokinetic Analysis)
Result:	C_max is 72,308 nM, observed clearance is 0.23 L/h and T_1/2 is 1.39 h.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (293.75 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9375 mL	14.6877 mL	29.3755 mL
5 mM	0.5875 mL	2.9375 mL	5.8751 mL
10 mM	0.2938 mL	1.4688 mL	2.9375 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (7.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.34 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.34 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.34 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。